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ABSTRACT
The human immunodeficiency virus (HIV) impacts up to 37 million people
globally. Although not fatal on its own, HIV can develop into acquired
immunodeficiency disease (AIDS), in which a person’s immune system becomes
compromised. To date, there is no cure for HIV, although many treatment options are
available. Despite their effectiveness, these treatments are commonly plagued by their
inherent complexity. Factors such as doing regimen, pill burden, and undesirable side
effects all contribute to variability in patient compliance, particularly in pediatric
populations. Currently, there is no anti-HIV drug product readily available for
pediatrics, despite close to 1.8 million children living with HIV. This is partially due
to a diverse patient population (ranging from birth till adolescence age) with specific
needs for various dosage forms and dosing unit size. In addition, taste preferences and
toxicity of excipients and may differ in children compared to adults.
In the present study, we aimed to develop a pediatric-friendly formulation for
anti-HIV therapeutics. Two protease inhibitors, lopinavir (LPV) and ritonavir (RTV)
(commercially available as Kaletra®), were chosen as model drugs. Kaletra® is a fixeddose combination (FDC) of LPV and RTV (4/1, w/w) in either a tablet or an oral
solution form. However, neither of these dosage forms is suitable for children. The
tablet is large, and therefore can be difficult to swallow for young children, especially
for children under four years who generally cannot swallow tablets. In addition, the
excipients used in the tablet formulation have been shown to induce adverse events in
a pediatric population. On the other hand, the oral solution contains upwards of 40%
ethanol and is not suitable for children. Both of these drugs exhibit very bitter taste

profiles, which children are very sensitive to. In addition, both LPV and RTV, are
inherently poorly water-soluble and suffer from low bioavailability. In order to
develop a pediatric-friendly formulation for FDC of LPV and RTV, it is critical to
improve dissolution and palatability of the therapeutics using safe excipient(s).
Cyclodextrins (CD) are cyclic oligosaccharides that can form water-soluble
complexes with hydrophobic drugs, and potentially enhance solubility and mask taste
of the therapeutics. In this study, two CD derivatives, 2-hydroxoypropyl-β-CD (HP-βCD) and 2-HP--CD were investigated. Phase solubility, isothermal titration
calorimetry (ITC), nuclear magnetic resonance (NMR) and molecular modelling
studies were conducted to determine interactions between them and the two anti-HIV
drugs, LPV and RTV. The results showed that complexes can be formed between drug
and CD and the optimal complexion ratio of drug/CD is 1:1. The results from each
study showed that RTV is capable of forming more stable complexes than LPV, with
both types of CD. Stability constant values calculated via phase solubility studies
indicated that β-CD formed more stable complexes with the drugs than -CD.
However, a different trend was obtained from the NMR and molecular modelling
studies, which showed that -CD formed more stable complexes. This suggested that
non-inclusion complex formation was favored, which NMR and modelling are less
sensitive to detecting, over traditional inclusion complex formation. These studies also
showed that the specific interactions that occurred between LPV and CD, and RTV
and CD, such as hydrogen bonding and hydrophobic interactions, were different, as
each drug has a fundamentally unique molecular structure.

Following this interaction analysis, formulation optimization of drug:CD
complexes was conducted. The prepared drug:CD complexes were spray dried to
obtain a final dry powder formulation. Solid state characterization of the spray-dried
complexes was performed to determine physicochemical characteristics such as
thermal profile, crystallinity, and morphology. Results showed that the spray-dried
complexes did not exhibit a melting temperature, and were comprised of drug in an
amorphous state, based on differential scanning calorimetry (DSC), X-ray diffraction
(XRD) and polarized light microscopy (PLM) data. In addition, scanning electron
microscopy (SEM) images showed that the spray-dried complexes exhibited a
corrugated, raisin-like morphology. In vitro dissolution studies showed that RTV in an
amorphous state exhibits a faster release profile than crystalline RTV. Spray-dried HPβ-CD/RTV complexes showed the most favorable dissolution profile, as 100% RTV
was released in 45 minutes. Unexpectedly, converting LPV from crystalline to
amorphous via spray-drying resulted in lower dissolution rate and extent. In addition,
spray-dried CD/LPV complexes did not exhibit favorable dissolution characteristics,
compared to the physical mixture of LPV, polymer, and CD.
Overall, interactions between both drugs and both CDs were characterized, and
CD/drug complexes were successfully prepared. Further studies will be conducted to
assess taste masking effect and in vivo bioavailability of the prepared drug/CD
complexes. In addition, other strategies such as freeze drying and kneading will be
investigated in the future to further optimize a suitable formulation with improved
dissolution characteristics for LPV.
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CHAPTER 1

INTRODUCTION

1.1 Background and Treatment of HIV
The human immunodeficiency virus (HIV) is a retrovirus that can lead to a
chronic, incurable disease that impacts upwards of 37 million people around the
world, of which approximately 1.8 million are children.1 Despite recent advancements
in anti-HIV therapeutics, HIV remains a major public health concern. In particular, the
virus remains an epidemic in regions of the world where resources are scarce.
Countries like Botswana and South Africa are plagued by the virus, and they represent
two of the regions in the world that have the largest population of HIV-infected
patients.2
HIV is capable of binding to various types of white blood cells, but most
commonly attaches to T lymphocytes through the CD4 receptor. Figure 1.1 illustrates
the replication process of HIV, where once the virus is inside the cell, it releases its
RNA and begins converting RNA to DNA using the enzyme reverse transcriptase.3
The conversion of RNA to DNA is inherently error prone, and therefore mutations
easily occur. After this step, newly synthesized viral DNA enters the cell nucleus and
becomes integrated with the cell’s DNA via the enzyme integrase. New viral RNA and
proteins are then produced from the DNA of the infected cell, and eventually a new
HIV virus is created. Finally, the virus buds through the cell membrane as the enzyme
HIV protease cleaves newly synthesized polyproteins, effectively creating a mature
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infectious virus.4 Ultimately, the virus is capable of spreading and infecting other
cells, destroying white blood cells, and weakening the body’s immune system. As a
result, the body is less able to fight off infections and can eventually succumb to one if
left untreated.

Figure 1.1. Schematic of an overview of the HIV replication process.5

The current standard in the treatment of HIV involves the use of antiretroviral
therapy (ART). ART is the combination of antiretroviral agents that target different
processes in the HIV replication cycle.6 This type of combination therapy has been
2

shown to be effective in dramatically suppressing viral replication and reducing HIV
plasma concentrations to below detectable limits.7 ART regimens vary based upon
factors including viral load, CD4 cell count prior to treatment, the results of the HIV
genotypic drug resistance test, and/or anticipated adherence.8 The World Health
Organization (WHO) has recommended a combination of tenofovir (TDF),
emtricitabine (FTC), and efavirenz (EFV) for those patients just beginning ART.9
Despite the effectiveness of combination therapy, major concerns remain
regarding patient adherence to such therapy. Since ART targets various underlying
mechanisms of HIV replication, numerous drugs are needed to ensure its
effectiveness, and as a result, the overall complexity of ART regimens has increased.
Factors such as dosing complexity, pill burden, dietary restrictions, and undesirable
side effects such as gastrointestinal (GI) intolerance including diarrhea, nausea, and
vomiting can contribute to the challenge of maintaining patient adherence to ART.10
The potential alternative, fixed-dose combinations (FDC), are advantageous as they
have been shown to improve patient adherence by reducing the pill burden faced by
those on a strict ART regimen.11 Therefore, the importance of developing FDC
formulations cannot be overlooked. Recently, scientists developed a formulation
containing rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor
(NNRTI), and cabotegravir (CAB), an investigational new drug that serves as an
integrase inhibitor. Phase II clinical trials were completed, and it was shown that
taking this formulation either once a month or once every two months, via
intramuscular injection, could effectively maintain viral suppression.12 This type of
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formulation is clearly advantageous, as most ART therapies require daily dosing to
achieve adequate viral suppression.
Kaletra® is an FDA-approved FDC product containing both lopinavir (LPV) and
ritonavir (RTV) available in a tablet form (400 mg/100 mg and 100 mg/25 mg
LPV/RTV) or as an oral solution (80 mg/mL LPV: 20 mg/mL RTV in 42.3% ethanol
and 15.3% propylene glycol).13 The structures of LPV and RTV are shown in Figure
1.2. LPV is a selective inhibitor of type 1 HIV (HIV-1) protease that works by
preventing viral maturation that ultimately results in the spread of infection.14
Administered alone, LPV has insufficient bioavailability due to extensive metabolism
by the cytochrome P450-3A4 (CYP3A4) enzymes, which is the primary class of
enzymes present in the liver responsible for metabolizing protease inhibitors.15 RTV is
a protease inhibitor, albeit a much less potent one than LPV, and is capable of
inhibiting CYP3A4 enzymes, and therefore aids in boosting the plasma concentration
of and increasing the bioavailability of LPV.16 A recent study investigated the
interaction between RTV and CYP3A4 enzymes and concluded that CYP3A4
inactivation results from RTV binding to Lys257 of the CYP3A4 apoprotein.17
Therefore, formulations containing RTV may require less frequent dosing due to the
protease inhibitor boosting effect, and may result in a reduction in side effects.18
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Figure 1.2. Chemical structures of (Left) lopinavir and (Right) ritonavir.

1.2 Pediatric Anti-HIV Formulations
Regardless of the disease, developing an oral pediatric formulation is often more
complex than developing one for adults, as there are more confounding variables that
impact overall performance. It has been shown that children exhibit fundamental
pharmacokinetic

differences

compared

to

adults,

including

gastrointestinal

permeability, rate of gastric emptying, and surface area available for drug
absorption.19 In addition, a child’s size, age, and taste preference can play a key role in
determining medication adherence, and ultimately overall effectiveness.20 A recent
review highlighted the challenges and potential solutions to developing pediatric
formulations. With respect to oral dosage forms such as pills and tablets, size is a very
important parameter when considering whether or not the formulation is safe for
pediatric patients. Children aged two-six years old can swallow mini-tablets (two mm
in diameter), however, larger tablets present a greater challenge.21
Although various treatments options exist for adults, there have been limited
efforts devoted to developing anti-HIV drug products suitable for pediatric
populations. Anti-HIV drugs are listed on the NIH’s Best Pharmaceuticals for

5

Children’s Act (BPCA) Priority Needs List for 2018-2019, which cites the specific
need to develop heat and light stable anti-HIV formulations with taste masking
abilities.22 Despite the effectiveness of combination therapy with RTV and LPV, these
two therapeutics have disadvantages such as poor water solubility and hence low
bioavailability, and bitter taste profiles.23 Drug products such as Kaletra® suffer from
drawbacks including large tablet size, making swallowing them extremely difficult for
children. In addition, the oral solution contains a large volume of ethanol, which is
especially unsuitable for pediatric patients. Furthermore, both tablet and solution
formulations are often associated with unwanted dose-dependent side effects such as
diarrhea, nausea, and vomiting.24
According to the Biopharmaceutics Classification System (BCS), both LPV and
RTV are characterized as Class II drugs, exhibiting low solubility and high
permeability, and hence variable bioavailability and high doses.25 There are a variety
of strategies that are commonly used to enhance dissolution, and hence oral
bioavailability, of poorly water-soluble drugs including micronization, micellar
formation, and complex formation.26 Recent studies have shown improved efficacy of
LPV and RTV using poly(lactic-co-glycolic acid) (PLGA) nanoparticles as the
delivery carrier, in addition to improved LPV absorption using an electrospray
encapsulation technique.27,28 Micronization techniques such as jet-milling and
homogenization result in an increased surface area to volume ratio, thus allowing for
more interaction between the drug particle surface and solvent and hence improved
dissolution.29 In the formation of micelles, amphiphilic molecules arrange themselves
into a spherical form, and hydrophobic drugs can form molecular interactions with the

6

inner hydrophobic core of micelles, thus enhancing the overall solubility of the drugmicelle system.30 In addition, lipophilic drugs can form complexes with carbohydrate
polymers such as cyclodextrins, thereby enhancing dissolution rate and solubility of
poorly water-soluble drugs.31

1.3 Cyclodextrin Complexes
Current challenges involved in the development of anti-HIV pediatric
formulations include the need to improve drug solubility and dissolution, improve
product stability, and provide taste masking effects. One potential approach aimed at
addressing these issues is the development of drug-cyclodextrin complexes. Shown in
Figure 1.3, cyclodextrins are six-, seven-, or eight-membered oligosaccharides formed
from the enzymatic degradation of starch.32 These supramolecular structures are coneshaped, exhibiting a hydrophilic outer shell comprised of primary and secondary
alcohol groups, and a hydrophobic core that can accommodate many non-polar
therapeutics by forming inclusion and non-inclusion complexes.33

Figure 1.3. Schematic diagrams of different types of cyclodextrin including α-, β-,
and γ-cyclodextrins.34
7

Drug-cyclodextrin complex formation arises when a drug is introduced to an
aqueous cyclodextrin solution, resulting in the removal of enthalpy-rich water
molecules from the hydrophobic cyclodextrin core. As water molecules are removed,
non-polar drug molecules are able to maneuver into the center of cyclodextrin cavities,
and form molecular interactions including hydrophobic, van der Waals, and
electrostatic interactions.31 No covalent bonds are formed or broken during this
process and bound drug molecules inside the cyclodextrin molecules are in dynamic
equilibrium with free drug molecules.35 The simplest and most common type of
complexation that can occur results in a binary system, in which only two different
types of molecules are used (i.e. drug and cyclodextrin). As shown in Figure 1.4, drug
and cyclodextrin molecules can form inclusion as well as non-inclusion complexes. As
seen in this figure, not all drug molecules will form inclusion complexes with
cyclodextrin molecules and it provides a much more realistic representation of
possible interactions between drug and cyclodextrin molecules. Despite this
complexity, drug-cyclodextrin complexes remain relatively simple to characterize.
Analytical techniques such as nuclear magnetic resonance, molecular modeling, and
isothermal calorimetry can be used to help explain the interactions between guest and
host compounds.
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Figure 1.4. Schematic diagram of drug-cyclodextrin complexes.36

Cyclodextrins have been used in various applications including use as food
additives, cosmetics, and pharmaceutical drug carriers.35 The toxicity of cyclodextrins
has been studied in recent years, and studies have shown no apparent toxicity from
cyclodextrin when developed as an oral formulation, mainly due to lack of absorption
in the GI tract.37 Native cyclodextrins (without modification) have limited aqueous
solubility, and therefore in recent years they have been chemically modified to
improve their aqueous solubility. 2-hydroxypropyl-beta-cyclodextrin (HP-β-CD) and
2-hydroxypropyl-gamma-cyclodextrin (HP-γ-CD) are two examples of cyclodextrin
derivatives that have enhanced solubility profiles compared to parent cyclodextrins.38
These modified cyclodextrins may be ideal candidates for pediatric formulations due
to their impressive safety profile, as recent studies have shown no apparent toxicity in
juvenile or adult rats.39
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Some work has previously been done to investigate techniques to improve the
solubility and dissolution profiles of LPV and RTV. A recent study showed that
cyclodextrin-LPV complexes can improve the in vitro dissolution profile of LPV, and
that more research is needed to utilize their full potential.40 However, in the described
study, dissolution studies were performed under sink conditions using 0.06 M
polyoxyethylene 10 lauryl ether, which does not accurately reflect the conditions of
the GI tract. Additionally, the study investigated the use of cyclodextrins on the
enhancement of LPV alone and did not investigate solubility enhancement strategies
for RTV.
Cyclodextrins not only aid in the enhancement of stability and solubility in
formulations, but they are also commonly employed for their taste masking abilities.
This is significant attribute because a major concern in developing pediatric
formulations is the palatability of the formulation. Studies have shown that children
have a low tolerance for poor-tasting medications, which may negatively impact
patient compliance, and overall medication effectiveness.20 One study concluded that
more than 90% of pediatricians reported that a drug’s taste and palatability presented
the largest obstacle to overcome for children completing treatment.41 Additionally,
many therapeutics, including LPV and RTV, have been reported as having very bitter,
unpleasant taste profiles.42 Cyclodextrins can act as taste masking agents by forming
complexes with bitter drugs, effectively shielding this property of the drug. A recent
study investigated the taste masking effect of HP-β-CD on ranitidine hydrochloride, a
common therapeutic used to treat a variety of GI diseases such as duodenal ulcer,
reflux oesophagitis, and Zollinger-Ellison Syndrome. It was concluded through the use
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of electronic taste sensing systems that increasing the molarity of cyclodextrin in a
formulation resulted in the reduction of bitter taste.43
In some instances, the solubility of binary drug-cyclodextrin complexes is rather
low, leading scientists to look for additional strategies to further enhance drug
solubility. It has been shown that the addition of water-soluble polymers, forming a
ternary formulation (i.e. drug-cyclodextrin-polymer), can enhance the traditional drugcyclodextrin complexation process, resulting in a system with improved water
solubility and stability.44 Other studies have corroborated this effect, showing that the
addition of water-soluble polymers to a drug-cyclodextrin system resulted in higher
drug solubility than when using cyclodextrin or polymer alone.45 Water-soluble
polymers can also aid in the overall stability of the final formulation, acting as drug
crystallization inhibitors.45 Despite these advantages, ternary systems are much more
difficult to analyze in terms of identifying specific molecular interactions occurring
between the drug, polymer, and cyclodextrin.
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CHAPTER 2

MATERIALS AND METHODS

2.1 Materials
Methanol (ChromasolvTM, ≥ 99%), hydrochloric acid, trifluoroacetic acid (TFA),
hydroxypropyl cellulose (HPC) and polyvinyl alcohol (PVA) were purchased from
Sigma Aldrich (St. Louis, MO). Phosphate buffered saline (PBS) and Hydranal KF
reagent were purchased from Fisher Scientific (Waltham, MA). 2-Hydroxypropyl-βcyclodextrin (HP-β-CD, MW: 1,400 Da) and 2-hydroxypropyl-γ-cyclodextrin (HP-γCD, MW: 1,540 Da) were generously provided by Wacker Chemical Corporation
(Adrian, MI). Lopinavir (LPV, MW: 628.80 Da) was purchased from AK Scientific
(Union City, CA). Ritonavir (RTV, MW: 720.94 Da) was purchased from eNovation
Chemicals (Bridgewater, NJ). Soluplus® and Kollidon® were kindly gifted by
Badische

Anilin-und

Soda-Fabrik

(BASF)

(Ludwigshafen,

Germany).

Polyvinylpyrrolidone (PVP, K30), PVP VA 64, and hydroxypropyl methylcellulose
(HPMC E15) were kindly gifted by JRS Pharmaceuticals (Patterson, NY). Deuterated
methanol (methanol-d4), deuterium oxide (D2O), and trymethylsilane (TMS) were
purchased from Cambridge Isotope Laboratories (Tewksbury, MA).

2.2 Phase Solubility Studies
Phase solubility studies of LPV and RTV were carried out in aqueous solutions
containing either HP-β-CD or HP-γ-CD from 1.25 mM to 20 mM. Samples were
prepared in triplicate and shaken at room temperature for 48 hours. The amount of
12

LPV and RTV in solution was determined using high performance liquid
chromatography (HPLC, Shimadzu Nexera I 2040c, Japan) with a Phenomenex C18
column (4.6  250 mm, 5 m). The mobile phase was composed of methanol/0.1%
TFA in water (85/15, v/v) at a flow rate of 1 mL/min and the injection volume was 20
L. Retention times were approximately 4.7 min for LPV and 3.9 min for RTV. A
phase diagram was created by plotting the concentration of cyclodextrin versus the
resulting drug solubility. For each drug:CD combination, these data were fit to a linear
regression. Stability constants (K1:1) were then calculated using the linear portion of
the phase solubility diagram according to the Higuchi-Connors equation below:46

K1:1 =

slope
S0 (1- slope)

where S0 is the solubility of drug in water, and the slope comes from the linear fit of
the plotted data.

2.3 Isothermal Titration Calorimetry (ITC)
ITC was used to analyze the thermodynamic parameters of interactions between
drug and CD at 298.15 K via a VP-ITC Microcalorimeter (MicroCal, Northampton,
MA, USA). A typical titration consisted of 20 consecutive injections of 12 µL of a
titrant with an interval of 210 s into a titration cell (containing CD). The CD solution
in the cell was stirred continuously at 307 rpm. Samples were prepared as follows:
stock solutions of LPV and RTV were made in methanol (1 mg/mL) and diluted down
in water to a final concentration of 0.04 mM. Stock solutions of HP-β-CD and HP-γCD were made in DI water (1 mg/mL) and diluted down in water to a final
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concentration of 0.004 mM. The samples were degassed for 20 min under vacuum
using a ThermoVac (MicroCal, Northampton, MA, USA) prior to each experiment.
Data were analyzed using nonlinear regression with a single-site binding model in VP
Viewer 2000, using the scientific plotting software, ORIGIN 7 (Origin Lab. Corp.,
Northampton, MA, USA). In particular, the data were used to determine the number of
binding sites (n, binding stoichiometry), inclusion enthalpy (ΔH), inclusion entropy
(ΔS), and Gibb’s free energy (ΔG) related to the drug:cyclodextrin binding. The
relationship between ΔS, ΔH, and ΔG can be described using the following equation:

DG = DH - TDS
where T is the temperature of the system.

2.4 Nuclear Magnetic Resonance (NMR) Analysis
All NMR titrations, 1H-NMR and 2D NMR, were performed in a Bruker 400
MHz NMR spectrometer at room temperature. Methanol-d4 and D2O were used as
solvents to determine any solvent effects. TMS was used as an internal standard. NMR
titrations were performed in two different directions to determine whether higher order
drug/CD complexations such as 1:2 or 2:1 occurred. First, the host molecule (i.e. HPβ-CD and HP-γ-CD) concentration was held constant (2 mM) while the guest (i.e.
LPV or RTV) concentration was varied from 0 to 25 mM. Then the host concentration
was varied from 0 to 60 mM while the guest concentration was held constant (6 mM).
The chemical shift data obtained from the NMR titration study was used to plot NMR
titration curves as described in Thordason's work.47 The software used for the non-
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linear curve fit model was BINDFIT, which is offered as a freeware from
supraolecualr.org.
Based on the change in chemical shift values as drug concentration increased,
stability constants based on 1:1 guest-host stoichiometry were calculated using the
following equations:

æ é HG ùû ö
Dd = d DHG ç ë
÷
è éë H 0 ùû ø
é HG ùû
Ka = ë
éë H ùû éëG ùû
Where Δ is the change in chemical shift value to concentration of complexes formed
([HG]), [H0] is the initial host concentration, and HG is the chemical shift at a
particular complex concentration. Ka is the stability constant to the concentration of
complexes formed ([HG]), concentration of free host ([H]), and concentration of free
guest ([G]).

2.5 Molecular Modelling
Molecular modelling was performed using Spartan16 and Molecular Operating
Environment (MOE) software. The models were first constructed in Spartan and were
then subjected to energy minimizations using molecular mechanics and semi-empirical
level calculations. Once the energy was minimized, further docking studies were
performed using MOE, where the host molecule (i.e. HP-β-CD and HP-γ-CD) was
treated as the receptor and the drugs were treated as ligands. AMBER force field was
used to perform the docking studies. The receptor and ligands were set for flexible
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alignment to ensure free movement. Once the docking was completed, docking scores
were tabulated, and ligand interactions were obtained to visualize the binding inside
the cavity of cyclodextrins.

2.6 Formulation optimization of drug-CD complexes
2.6.1 Binary Complex Formation
Binary drug-CD complexes were initially formed at a 1:1 molar ratio of drug/CD.
According to the phase solubility diagrams, 5 mM was chosen as an appropriate
concentration to use for the formation of drug/CD complexes. A 10 mM stock solution
of each drug was prepared in methanol and a 10 mM stock solution of each CD was
prepared in DI water. 25 mL of 10 mM drug solution was slowly added to a beaker
containing 25 mL of CD solution under continuous stirring at 360 rpm for 6 hours at
room temperature. An overview of the complexation process can be seen in Figure
2.1. The mixture was filtered, and spray-dried using a Buchi B-290 spray dryer
coupled with a B-295 inert loop (Büchi Labortechnik, AG, Switzerland) in closed
mode as seen in Figure 2.2. The following spray drier parameters were kept constant:
0.7 mm nozzle diameter, inlet temperature of 100°C, pump flow rate of 3 mL/min, gas
flow rate of 414 L/h, nozzle cleaner rate of 0, and aspiration rate of 40 m3/h. The dry
samples were collected and stored at -20°C for further use.
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Figure 2.1. Schematic overview of the drug:cyclodextrin (CD) complexation process,
where drug was dissolved in methanol and CD was dissolved in water, followed by the
combination of these two solutions to allow for drug:CD complex formation.

Figure 2.2. Schematic of overview of spray drying process, where feed solutions were
added to the spray dryer to be dried and collected as micron-size particulates in the
particle collection chamber.
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2.6.2 Ternary Complex Formation
The effect of various hydrophilic polymers (e.g. PVP K30, PVP VA 64, HPMC
E15, Soluplus®, and Kollidon®) on the solubility improvement of LPV and RTV in the
presence of HP-β-CD, and HP-γ-CD was investigated. The polymer showing the
greatest enhancement was used to form ternary drug-CD-polymer complexes. Ternary
complexes consisting of drug-CD-polymer were produced in a similar manner as the
binary complexes as described in Section 2.6.1 above. The final complex formulation
contains 1% (w/v) polymer.

2.7 Physicochemical Characterization of the Complexes
2.7.1 Solubility Study
Solubility studies of final complex formulations were performed in millipore
water. Saturated solutions were prepared by adding each formulation into vials until
visible precipitate was observed (indicating saturation). Samples were prepared in
triplicate and shaken 37°C for 48 hours. The amount of LPV and RTV in solution was
determined using HPLC, as described in Section 2.2.

2.7.2 Differential Scanning Calorimetry (DSC)
Thermal behavior of the raw compounds and spray-dried ternary drug/CD
complexes were analyzed using a TA Q10 DSC system (TA Instruments, New Castle,
DE) connected to an RSC-90 cooling accessory. Approximately 5 mg of each sample
was hermetically sealed in an aluminum pan and analyzed at 10°C/min from 0 to
200°C. An empty, sealed aluminum pan was used as reference.
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2.7.3 X-Ray Diffraction (XRD)
The crystallinity of the raw compounds and spray-dried ternary drug/CD
complexes was determined using a Rigaku Multiflex X-ray diffractometer (The
Woodlands, TX) with a Cu Kα radiation source of 40 kV and 44 mA. Samples were
placed on a 3 mm horizontal quartz glass holder prior to analysis. Scans were taken
from 5-60° in 2 with a step width of 0.2 and a scan rate of 2°/min.

2.7.4 Polarized Light Microscopy (PLM)
Samples of raw drugs and spray-dried ternary drug/CD complexes were obtained
and analyzed for birefringence activity using an AmScope polarized microscope
(Irvine, CA). Samples were mounted onto microscope slides, dispersed in mineral oil,
and imaged at 10x magnification at room temperature.

2.7.5 Scanning Electron Microscopy (SEM)
The morphology of the raw drugs and spray-dried ternary drug/CD complexes
were analyzed via a Zeiss Sigma VP Field Emission-SEM (FE-SEM, Germany). Dry
powder samples were placed on aluminum SEM stubs (Ted Pella, Inc., Reading, CA)
via adhesive carbon tabs. Samples were sputter coated with a film of gold/palladium
alloy using a BIO-RAD sputter coating system at a 20 µA for 75 seconds under argon.
Images were taken at 7.0 kV and 7,500x, 15,000x, and 28,000x.

2.7.6 Moisture Content
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The moisture content of the spray-dried ternary drug/CD complexes was
measured via Karl Fischer (KF) titration using a 737 KF coulometer (Metrohm,
Riverview, FL). Approximately 3-5 mg of sample was dissolved in anhydrous
methanol before being injected into the reaction cell filled with Hydranal® reagent.
Water content was then quantified using anhydrous methanol as the reference sample.

2.8 In Vitro Dissolution Studies
In vitro dissolution studies were carried out using a USP apparatus II method
(Sotax AT Xtend apparatus, Allschwil, Switzerland) at 37°C with a paddle speed of 75
rpm. 100 mg LPV and 25 mg RTV pure drugs or drug/CD complexes were transferred
to dissolution vessels containing release media i.e. 0.1 N HCl (pH 1.09) and 10 mM
PBS (pH 6.8). At predetermined time intervals, release media were withdrawn and
replenished with fresh media. The dissolution samples were filtered using a 0.45 µm
syringe filter (polyvinylidene fluoride, PVDF) and analyzed via HPLC.
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CHAPTER 3

RESULTS AND DISCUSSION

The present study investigated the use of two CD molecules (i.e. HP-β-CD and
HP-γ-CD, Figure 1.3) and evaluated their impact on enhancing the solubility and
dissolution profiles of two anti-HIV model therapeutics, lopinavir (LPV) and ritonavir
(RTV). Initial phase solubility studies were performed to determine the effect of
cyclodextrin concentration on drug solubility. Interactions between the drugs and
cyclodextrin molecules were investigated via analytical techniques such as NMR, ITC,
and molecular modeling. A water-soluble polymer, Soluplus®, was also included in
the formulation in an effort to further enhance drug solubility and dissolution profiles.
Final formulations were created following drug:CD:Soluplus® complexation and spray
drying to produce micro-sized dry particulates, which were characterized for their
morphology, thermal stability and crystallinity, water content, and in vitro dissolution.

3.1 Phase Solubility Studies
One of the major challenges of the described study was the need to improve the
water solubility of two poorly-soluble small molecule drugs, LPV and RTV. Table 1
shows the molecular weight and solubility of LPV and RTV in water and in 0.1 N
HCl, where both drugs exhibited aqueous solubilities below 10 µM. The solubility of
RTV in 0.1 N HCl was significantly higher than LPV, mainly as a result of the
protonation ability of thiazole groups present in RTV (Figure 1.2). In addition, LPV
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solubility decreased nearly 10-fold in acidic conditions (compared to water), whereas
RTV increased 585-fold.

Table 1. Molecular weight and solubility values of lopinavir (LPV) and ritonavir
(RTV) in water and 0.1 N HCl.
Drug Solubility (37°C)
(µM)
Drug MW (Da)

Water

0.1 N HCl

LPV

628.81

6.66 ± 0.05

5.57 ± 0.50

RTV

720.95

0.87 ± 0.19

512 ± 16

A solubility enhancement technique that is commonly used for poorly-soluble
drugs is the cyclodextrin complexation approach, in which drug molecules can interact
with cyclodextrin molecules to form either inclusion or non-inclusion complexes
(Figure 1.4). In an initial attempt to increase LPV and RTV solubility, phase
solubility studies of LPV and RTV were carried out in aqueous solutions containing
increasing concentrations of HP-β-CD or HP-γ-CD from 1.25 mM to 10 mM. This
initial study was vital in that it helped elucidate the effect of CD concentration on drug
solubility. Figure 3.1 shows that both CDs enhanced the solubility of LPV and RTV
with increasing CD concentration. These data were fitted to a linear equation to
indicate the linear relationship between CD concentration (x) and drug solubility (y).
Based on the Higuchi-Connors classification of phase solubility profiles (Figure A.1),
the A-type phase solubility profiles were obtained for each system, indicating that
solubility of the substrates increased (i.e. drug) with increasing ligand (i.e.
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cyclodextrin) concentration.48 More specifically, the relationship between each drug
and CD were found to exhibit AL-type phase solubility profiles (Figure A.1), in which
the complex is first-order with respect to the ligand and first or higher order with
respect to the substrate. While phase solubility studies cannot be used to determine the
formation of inclusion complexes, they can be used to show the influence of
increasing CD concentration on drug solubility. In addition, it is most often the case
that AL-type phase solubility profiles result in complexes occurring in a 1:1 molar
ratio.46

Figure 3.1. Phase solubility analysis of lopinavir (LPV) and ritonavir (RTV) in the
presence of varying concentrations of 2-hydroxypropyl-β-cyclodextrin (β-CD) or 2hydroxypropyl-γ-cyclodextrin (γ-CD).
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Stability constants (K1:1) were calculated from the functions generated in Figure
3.1 using the Higuchi-Connors equation, assuming 1:1 drug:CD stoichiometry. K1:1
values depend on the solubility of a drug in water, and are often calculated using the
intrinsic solubility (Sint) from phase solubility diagrams, where Sint is where the linear
plot passes through the y-axis. The calculated Sint values often do not reflect the true
solubility of a drug, since they are based upon extrapolation. As a result, K1:1 values
were also calculated based on the experimental solubility data (S0) for both drugs
(Table 1).
K1:1 can be used to determine the strength of interactions between a drug and CD.
Based on the values in Table 2, the strength of interactions between β-CD and LPV
and γ-CD and LPV were similar, as evidenced by their comparable K1:1 values.
Despite this similarity, the K1:1 for β-CD and LPV was higher than γ-CD and LPV,
indicating that β-CD may form stronger complexes with LPV than γ-CD. This has
been previously shown in literature, with the explanation that β-CD has a slightly
smaller cavity than γ-CD, allowing for a better fit and intermolecular interactions
between β-CD and LPV.37 The interactions between β-CD and RTV were much higher
than those between γ-CD and LPV, as indicated by the nearly 3-fold increase in K1:1,
which is likely due to the smaller β-CD cavity as discussed above.
With respect to how S0 and Sint impact K1:1, the binding constants based on S0 for
β-CD or γ-CD and LPV were similar to the binding constant values calculated from
Sint. The K1:1 for γ-CD and RTV based on Sint were higher than the K1:1 values based
on S0. The binding constant based on Sint for β-CD and RTV was unable to be
calculated due to a negative y-intercept value from the phase stability diagram,
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however, K1:1 was successfully calculated using S0. Overall, the calculated K1:1 values
were between 250 and 150 M-1, with the β-CD resulting in the highest K1:1 values for
both drugs. The reported trends are in good agreement with similar studies conducted
on guest-host interactions involving β- and γ-CD.37

Table 2. Phase solubility analysis of lopinavir (LPV) and ritonavir (RTV) with 2hydroxypropyl-β-cyclodextrin (β-CD) or 2-hydroxypropyl-γ-cyclodextrin (γ-CD).
Stability constant (K1:1) values were calculated based on both the experimental drug
solubility in water (S0) and y-intercept value (Sint) from the phase solubility data from
Figure 1.

S0
(µM)
-CD+LPV
-CD+LPV

Sint
(µM)

K1:1
(from S0)
(M-1)

K1:1
(from Sint)
(M-1)

6.5

316

324

6.6

286

288

---

1490

---

0.7

572

715

6.66

-CD+RTV
0.87
-CD+RTV

3.2 Isothermal Titration Calorimetry (ITC)
ITC was used to confirm the binding stoichiometry between each drug and
cyclodextrin. ITC is an analytical technique used to determine the stability and
thermodynamics of cyclodextrin inclusion compounds in solution.49 It can be used to
determine parameters such as number of binding sites (n, binding stoichiometry),
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inclusion enthalpy (ΔH), inclusion entropy (ΔS), and Gibb’s free energy (ΔG) related
to the drug:cyclodextrin binding. ITC allows for the measurement of the heat absorbed
or released during complex formation as a drug is titrated into a CD solution.
Typically, for guest-host (drug-CD) interactions, the complexation process is
exothermic, as enthalpy-rich water molecules evacuate the CD cavity, making room
for the more hydrophobic guest molecules. The amount of heat released due to
complexation is proportional to the binding enthalpy of the system and to the number
of complexes formed.49 Non-linear curve fitting is used to generate the binding
isotherm for each system, as depicted in Figure 3.2.
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Figure 3.2. Isothermal titration calorimetry (ITC) binding isotherms generated via
non-linear curve fitting for each drug:cyclodextrin system (RTV = ritonavir, LPV =
lopinavir, β-CD = 2-hydroxypropyl-β-cyclodextrin, and γ-CD = 2-hydroxypropyl-γcyclodextrin).
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Based on the values of n listed in Table 3, it is evident that the binding
stoichiometry between each drug and each CD is 1:1, since all values are near 1,
confirming the results of the phase solubility analysis. The ΔH and ΔS values can be
used to determine the specific types of interactions that occur during drug:CD
complexation. In particular, the binding enthalpy reflects the guest-host interactions in
terms of van der Waals interactions and hydrogen bonding, whereas the entropy is a
reflection of hydrophobic interactions between the guest and host.50 Based on the
results, each system exhibited a negative binding enthalpy and a negative change in
entropy, indicating that both van der Waals interactions and hydrophobic interactions
were involved in the complexation processes.
The Gibb’s free energy value for each system was found to be negative,
indicating that complexations were exothermic, spontaneous processes. ΔG values for
RTV for both CD were higher than ΔG values calculated for LPV systems. This
indicates that RTV can form more stable complexes than LPV, which is supported by
phase solubility studies that showed increased binding constant values for RTV than
LPV. Overall, these data show that the binding stoichiometry for each system was 1:1
(drug:CD) based on the calculated n values, and that multiple types of interactions
play a role in the complexation processes. The binding stoichiometry between drug
and CD is a vital piece of information needed during formulation development.
Lastly, the calculated ΔG values for each system were found to be negative, indicating
spontaneous complex formation.51
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Table 3. Isothermal titration calorimetry data showing binding stoichiometry (n),
enthalpy contribution (ΔH), entropy contribution (TΔS), and calculated Gibb’s free
energy (ΔG) of each system (RTV = ritonavir, LPV = lopinavir, β-CD = 2hydroxypropyl-β-cyclodextrin, and γ-CD = 2-hydroxypropyl-γ-cyclodextrin).
n

ΔH
(kcal/mol)

TΔS
(kcal/mol)

ΔG
(kcal/mol)

β-CD+LPV

1.00

-123

-115

-8.0

-CD+LPV

1.08

-95

-87

-8.0

β-CD+RTV

1.09

-140

-131

-9.0

-CD+RTV

0.97

-228

-219

-9.0

3.3 Nuclear Magnetic Resonance (NMR)
NMR was used to investigate the changes in chemical shifts of particular protons
present in CD molecules when exposed to varying drug concentrations, which can
then be used to generate predicted stability constant value and binding stoichiometry
of each drug:CD system. NMR titration experiments were performed two different
ways. The first method involved keeping the host (CD) concentration constant and
varying the guest (drug) concentration, and the other method involved keeping the
guest concentration constant and varying the host concentration. This allows for the
prediction of stability constants associated with higher order complexes (1:2 and 2:1)
based on mathematical equations that relate the concentration of the complexes
formed, initial host concentration, and changes in chemical shift values. Chemical
shift values are directly proportional to the concentration of host-guest complexes and
original host concentration (as shown in Figures A.2-A.9). In this study, changes in
chemical shift values (Δδ) were not found to be consistent with the formation of
29

higher order complexes, as indicated in Table 4, as no stability constants were
available for 1:2 and 2:1 complexations.

Table 4. Stability constant values calculated for drug:cyclodextrin interactions using
changes in chemical shift values obtained via NMR titration studies (RTV = ritonavir,
LPV = lopinavir, β-CD = 2-hydroxypropyl-β-cyclodextrin, and γ-CD = 2hydroxypropyl-γ-cyclodextrin).
Stability Constant (M-1)

Binding stoichiometry
1:1

1:2

2:1

β-CD + LPV

308

N/A

N/A

-CD + LPV

669

N/A

N/A

β-CD + RTV

1320

N/A

N/A

-CD + RTV

1590

N/A

N/A

Figure 3.3 represents the NMR titration curves obtained using the method where
the CD concentration was kept constant and the drug concentrations were varied. The
chemical shift value that corresponds to a particular drug molecule is on the x-axis,
and the concentration of drug is denoted on the y-axis. For β-CD+LPV, the chemical
shift values present (6.91 to 7.00 ppm) correspond to the aromatic ring structure
protons containing two methyl groups in LPV. For LPV+γ-CD, the chemical shift
values present (7.26 to 7.28 ppm) correspond to one of the two benzene rings in LPV.
For both RTV+β-RTV and RTV+γ-CD, the chemical shift values (7.21 to 7.22 ppm)
correspond to the benzene structure present in RTV. For all drug:CD complexations,
as the concentration of LPV increased, the chemical shift values increased and shifted
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to the right, which indicates that these protons are being shielded, an event that
commonly occurs during complexation between guest-host molecules.52 These results
indicate that successful complexation occurred between LPV or RTV and the two CD.

Figure 3.3. NMR titrations for (A) lopinavir (LPV) and 2-hydroxypropyl-βcyclodextrin (β-CD), (B) LPV and 2-hydroxypropyl-γ-cyclodextrin (γ-CD), (C) RTV
and β-CD, and (D) RTV and γ-CD. Analysis was performed while holding the host
(CD) concentration constant (2 mM) while the drug concentration ranged from 0-25
mM.

The stability constants (Ka) were calculated from the NMR data were slightly
different from the experimental data. The Ka values listed in Table 4 indicate that γCD has the potential to form more stable complexes than β-CD for both LPV and
RTV. These results are contrary to those discovered during the phase solubility
31

studies, which indicated that β-CD forms were more stable complexes than γ-CD with
the two drugs. This may be explained by the fundamental differences in the way the
stability constant is calculated for each experiment. In the phase solubility study
experiment, the stability constant is calculated based on regression analysis of
experimental solubility data, and this study involves saturating each aqueous solution
with pure, undissolved drug. In contrast, in NMR experiments the trials were
performed in deuterated methanol, allowing both drugs to remain in solution for the
entirety of the titration. These experimental differences may affect the trends
associated with guest-host interactions, and may therefore impact the calculated
stability constant values. Overall, the NMR studies were able to confirm 1:1
stoichiometry between the guest and host during complexation.

3.4 Molecular Modelling
Molecular modelling was performed to determine the most stable conformation
(pose) for each drug:CD pairing. Each drug was constructed in the software, and
energy minimization and docking studies were performed, where the host molecule (βCD or γ-CD) was treated as the receptor and the guest molecule (LPV or RTV) was
treated as the ligand. The five most stable conformations, based on drug:CD
interactions, were obtained. The docking scores, which represent the predicted values
of the free energy of binding between drug and CD, are recorded in Table 5. Based on
these data, γ-CD exhibited lower free energy values than β-CD upon interacting with
either LPV or RTV, indicating that γ-CD can form more stable complexes with these
two drugs compared to β-CD. These results do not correlate well with phase solubility
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results, in which β-CD was found to have higher binding constants for both drugs
compared to γ-CD. One reason for this could be that in modeling studies only the
lowest free energy conformations are examined, which are based on ideal conditions
in the computational method. In addition, molecular modelling studies do not take into
account non-inclusion based phenomena, in which drug and cyclodextrin complexes
interact with one another to further aid in solubilization. Figure 1.4 shows a more
realistic scenario involving a variety of interactions between the drug and CD that can
involve inclusion complexes, non-inclusion complexes, and CD-based micellar-like
structures that can surround and encapsulate drug molecules. Despite this, the most
stable conformations exhibit docking scores between -7 and -9 kcal/mol, which
correlates well with the ΔG values calculated in the ITC studies. The docking scores
that correspond to the most stable conformations for β-CD + LPV, γ-CD + LPV, β-CD
+ RTV, and γ-CD + RTV are -7.29, -7.54, -7.12, and -8.73 kcal/mol, respectively.
Negative docking score values indicate that complexation can occur spontaneously
and is an exothermic process, which supports the data from ITC studies.
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Table 5. Docking scores of the five most stable conformations (poses) of β-CD +
LPV, γ-CD + LPV, β-CD + RTV, and γ-CD + RTV (RTV = ritonavir, LPV =
lopinavir, β-CD = 2-hydroxypropyl- β-cyclodextrin, and γ-CD = 2-hydroxypropyl-γcyclodextrin).

Docking Score (kcal/mol)
Conformer

β-CD+LPV

-CD+LPV

β-CD+RTV

-CD+RTV

Pose 1

-7.2895

-7.5365

-7.1190

-8.7313

Pose 2

-7.2343

-7.4682

-7.1106

-8.0085

Pose 3

-7.0827

-7.2982

-6.9980

-7.7874

Pose 4

-6.9578

-7.2553

-6.9615

-7.6955

Pose 5

-6.9211

-7.2239

-6.9473

-7.6637

Following the docking score evaluation, the most stable conformation of each
system was selected in order to visualize the potential interactions between each drug
and CD, as shown in Figure 3.4. From these models, it is possible to investigate the
specific interactions involved in the complexation process, and is particularly helpful
in gaining insight into the interactions that occur in the CD cavity. In addition, in each
two-dimensional figure, the blue shaded regions represent the portions of the drug
molecule that are exposed (not located inside of the CD cavity).
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Figure 3.4. Molecular modeling studies investigating interactions between β-CD +
LPV, β-CD + RTV, γ-CD + LPV, and γ-CD + RTV (RTV = ritonavir, LPV =
lopinavir, β-CD = 2-hydroxypropyl-β-cyclodextrin, and γ-CD = 2-hydroxypropyl-γcyclodextrin).

For β-CD+LPV it appears that one of the aromatic regions of LPV is able to
insert itself into the CD cavity. This conformation likely occurs because the interior of
the CD cavity is hydrophobic relative to the exterior, and the drug aromatic rings are
inherently hydrophobic due to the C-C and C-H bonds that comprise their structure. It
is also likely that hydrogen bonding, in addition to van der Waals interactions play a
key role in complex stabilization, as denoted by the blue and yellow dashed lines,
respectively. It appears that hydrogen bonds can form between the hydroxyl groups
located on the wider rim of the CD molecule and the double-bonded oxygen carbonyl
groups found on LPV. For β-CD+RTV the structure of RTV is inherently different
than the structure of LPV, which results in different interactions between each drug
and CD molecule. RTV contains two thiazole groups, which can act as hydrogen
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acceptors that can readily participate in hydrogen bonding. This phenomenon can be
confirmed from the modeling simulation, where the sulphur atom in the thiazole group
interacts with exterior rim hydroxyl groups on the CD molecule. In addition, the
terminal isopropyl group present in RTV is capable of inserting itself into the CD
cavity, a process most likely driven by hydrophobic interactions, as high energy water
molecules release from the CD cavity, making room for hydrophobic moieties.
Additional hydrogen bonding occurs between CD hydroxyl groups and other protons
present in RTV, which further aids in complex stabilization.
γ-CD+LPV interactions were similar to β-CD+LPV interactions. From the model,
extensive hydrogen bonding occurs, especially between the carbonyl located on the
pyrimidine on LPV and protons located on the outer CD rim. In addition, hydrogen
bonding occurs between the amine group of the pyrimidine on LPV and the hydroxyl
group on the CD rim. For γ-CD+RTV one of the thiazole groups in RTV appears to
insert itself into the CD cavity and extend straight through to the back of the CD
molecule. It is like that hydrogen bonding occurs between the inserted RTV moiety
and hydroxyl groups present on the narrow rim of the CD. This phenomenon may be
due to the increased size and internal volume of the γ-CD cavity, as a result of it being
comprised of an additional glucopyranose unit, in comparison to β-CD. These
phenomena may also explain why γ-CD+RTV exhibits the lowest docking score, and
thus results in the most stable conformation. In particular, more of the drug molecule
is able to insert itself into the CD cavity, and interactions occur with the narrow rim of
the CD molecule. In addition, the other thiazole group present on RTV appears to
hydrogen bond to exterior protons on the CD rim. Overall, these molecular modeling
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studies were able to provide a unique look into how drug and CD molecules form
complexes. Many interactions can form between drugs and CD, however, extensive
hydrogen bonding between the drug and exterior rim hydroxyl groups appears to
provide a significant stabilizing effect. In addition, hydrophobic interactions appear to
play a key role in forming stable complexes.

3.5 Binary and Ternary Complex Formation
Phase solubility studies were initially conducted to investigate the influence of
increasing CD concentration on drug solubility. Based on these values, further studies
were performed to enhance the solubility of the drugs in solution with CD through the
addition of a hydrophilic polymer. Various water-soluble polymers such as PVP,
Soluplus®, Kollidon®, HPC, PVA, and HPMC were investigated. Figure 3.5 shows
that Soluplus® was the polymer that resulted in the greatest enhancement in solubility
for both LPV and RTV. Upon Soluplus® exposure, LPV solubility increased 146-fold
and RTV solubility increased 17-fold in comparison to solubility analysis in only
water. For both LPV and RTV, the addition of Soluplus® enhanced their solubility in
water. Moreover, the addition of Soluplus® enhanced the solubility further than CD
alone.
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Figure 3.5. Solubility analysis of (Top) lopinavir (LPV) and (Bottom) ritonavir (RTV)
in the presence of various polymers (0.5 weight%) in aqueous media.

A follow-up solubility study was conducted to determine the optimal
concentration of Soluplus® to use in final formulations containing drug, CD, and the
polymer.

Soluplus®

is

a

poly(ethylene

glycol)-polyvinyl

acetate-

polyvinylcaprolactame-based grafted copolymer that is amphiphilic, containing both
hydrophilic and hydrophobic moieties, which provides an ideal platform to form
interactions with hydrophobic drugs while maintaining water solubility. Soluplus® has
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been shown to not only improve solubility of poorly water-soluble drugs, but also aids
in the stability of formulations, acting as a crystal growth inhibitor for drugs in
amorphous solid dispersions.53 As seen in Figure 3.6, 1 wt% of Soluplus® resulted in
the maximum enhancement in solubility for both drugs. The addition of Soluplus® had
the greatest impact on the solubility of LPV in comparison to RTV. Based on these
results, ternary formulations were prepared that include drug, CD, and Soluplus®.
Following mixing and inclusion formation, these solutions were spray dried to form
dry micron-based particles that represent to the final formulation products, denoted as
γ-CD/LPV/SOL, β-CD/LPV/SOL, γ-CD/RTV/SOL, and β-CD/RTV/SOL.
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Figure 3.6. Solubility analysis of (Top) lopinavir (LPV) or (Bottom) ritonavir (RTV)
in water, 5 mM 2-hydroxypropyl-β-cyclodextrin (β-CD), or 5 mM 2-hydroxypropyl-γcyclodextrin (γ-CD) in the presence of varying amounts (weight %) of Soluplus®.
As shown in Figure A.10, ternary complexes showed significantly higher
solubility compared to the pure drugs (p<0.05 for β-CD/LPV/SOL, β-CD/RTV/SOL,
and γ-CD/RTV/SOL, and p<0.001 for γ-CD/LPV/SOL).
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3.6 Thermal Analysis of Spray-Dried Microparticles
Thermal analysis of the spray dried formulations and raw compounds was
performed using differential scanning calorimetry (DSC). As shown in Figure 3.7, a
strong endothermic peak was evident at 113°C for raw LPV, which indicates the
melting temperature of LPV. Similarly, a strong endothermic peak was present at
130°C for raw RTV, which indicates the melting temperature of RTV. These results
are in agreement with previously reported LPV and RTV melting temperatures.54 Raw
β-CD exhibited a glass transition near 149°C, and γ-CD exhibited a glass transition
near 156°C. The sharp, endothermic peaks that correspond to raw LPV and RTV
disappear after spray-drying each drug, which is an indication that the drugs transition
from crystalline to amorphous states during the spray-drying process.
Spray-drying is a process where dry powders are created from a feed solution
containing the formulation components. The feed solution is fed through a small
diameter nozzle, forming atomized droplets of solution. Depending on temperature
and solvents used, most of the solvent is quickly vaporized, and the droplets quickly
condense into a dry powder for collection. Since the solution is heated, drug molecules
that are initially arranged in an orderly, crystalline structure become excited and
rearrange themselves into a more unstable, higher energy amorphous arrangement.
This amorphous solution solidifies as it is quickly cooled. As a result, when pure drug
is spray dried, its crystalline properties are lost, and thus its melting temperature
disappears. The molecules no longer exhibit long order arrangement, and so the bonds
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between drug molecules have different strengths. Therefore, there is no single amount
of heat required to break the bonds; instead it requires a range of energies.

Figure 3.7. Differential scanning calorimetry thermograms indicating thermal
transitions corresponding to (Top) lopinavir (LPV) samples and (Bottom) ritonavir
(RTV) samples. β-CD = 2-hydroxypropyl-β-cyclodextrin, γ-CD = 2-hydroxypropyl-γcyclodextrin, and SOL = Soluplus®. β-CD/drug/SOL and γ-CD/drug/SOL refer to the
final formulation samples.
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Thus, the DSC thermograms indicate amorphous drug formation in both spraydried LPV and RTV. Similarly, the final spray-dried formulations displayed
amorphous characteristics. These results make sense, as β-CD, γ-CD, and Soluplus®
are originally amorphous, and spray-dried drugs also

exhibit amorphous

characteristics.

3.7 Crystallinity Analysis of Spray-Dried Microparticles
The crystallinity of pure compounds as well as spray-dried formulations was
further examined using X-Ray diffraction (XRD). It can be seen in Figure 3.8, both
raw β-CD and γ-CD exhibited smooth diffractograms, with an absence of strong
peaks. These results, in agreement with the DSC data, indicate that these compounds
are amorphous. On the contrary, raw LPV and RTV exhibit a multitude of strong
peaks between 8-25 degrees. These sharp peaks indicate that LPV and RTV are
crystalline, which is supported by the DSC data. The final spray-dried formulations
exhibit broad peaks around 18 degrees. These broad peaks indicate that the
compounds present in the sample are amorphous, as the molecules exhibit a random,
disordered molecular arrangement.
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Figure 3.8. X-ray diffraction patterns of (Top) lopinavir (LPV) and (Bottom) ritonavir
(RTV) samples. β-CD = 2-hydroxypropyl-β-cyclodextrin, γ-CD = 2-hydroxypropyl-γcyclodextrin, and SOL = Soluplus®. β-CD/drug/SOL and γ-CD/drug/SOL refer to the
final formulation samples.

3.8 Polarized Light Microscopy (PLM)
Polarized light microscopy (PLM) was used to confirm the phases of the spraydried formulations and their constituents. PLM is a type of optical microscopy
technique in which light is passed through a polarized lens, only allowing light
traveling along a particular plane through to the specimen. Samples that exhibit
birefringence (materials that have refractive indices dependent on plane-polarized
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light) can be observed using this technique. Materials that are crystalline often exhibit
birefringence, which can be confirmed via PLM. Figure 3.9 contains representative
PLM images for raw compounds and spray-dried formulations containing LPV. Raw
β-CD and γ-CD appear amorphous by the lack of birefringence, which is supported by
DSC and XRD data. It is evident that pure LPV is crystalline, as shown by the visible
crystal-like structures exhibiting birefringence. Spray-dried LPV shows no
birefringence and supports the claim that spray drying can convert crystalline drug to
an amorphous form. Four sets of physical mixtures (PM) were imaged, including PM
β-CD+LPV, PM γ-CD+LPV, PM β-CD+LPV+SOL, and PM γ-CD+LPV+SOL. These
samples all exhibited some degree of birefringence, indicating that LPV remained in a
crystalline form when mixed with CD and Soluplus® during simple physical mixing.
The final spray-dried formulations were also imaged, including the binary
formulations β-CD/LPV and γ-CD/LPV, in addition to the ternary formulations βCD/LPV/SOL and γ-CD/LPV/SOL. These samples exhibited a lack of birefringence
and visible dark spots, indicating that they were amorphous.
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Figure 3.9. Polarized light microscopy images obtained for lopinavir (LPV) samples.
β-CD = 2-hydroxypropyl-β-cyclodextrin, γ-CD = 2-hydroxypropyl-γ-cyclodextrin, and
SOL = Soluplus®. β-CD/drug/SOL and γ-CD/drug/SOL refer to the final formulation
samples. Scale bar = 25 m.

Corresponding RTV samples were imaged, as shown in Figure 3.10. The same
trends occurred for RTV samples as did for LPV samples. Pure RTV was crystalline,
whereas spray-dried drug appeared amorphous. All four physical mixtures containing
RTV exhibited some degree of birefringence, indicating that RTV remained in its
crystalline form. On the contrary, spray-dried formulations containing RTV appeared
amorphous, which is consistent with orthogonal solid-state characterizations
performed on these samples. Overall, the results obtained from PLM were consistent
with other experiments conducted in this study and no contradictions were observed.
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Figure 3.10. Polarized light microscopy images obtained ritonavir (RTV) samples. βCD = 2-hydroxypropyl-β-cyclodextrin, γ-CD = 2-hydroxypropyl-γ-cyclodextrin, and
SOL = Soluplus®. β-CD/drug/SOL and γ-CD/drug/SOL refer to the final formulation
samples. Scale bar = 25 m.

3.9 Scanning Electron Microscopy (SEM)
SEM images were taken of raw and spray-dried drugs and final ternary
formulations to investigate their size and morphology. As seen in Figure 3.11, pure
LPV appears crystalline and rectangular in nature, exhibiting a size close to 20 µm.
Analogously, raw RTV exhibits a very ordered structure, with narrow, stick-like
morphology, with crystals greater than 10 µm in length. The final formulations (i.e. βCD/LPV/SOL, γ-CD/LPV/SOL, β-CD/RTV/SOL, and γ-CD/RTV/SOL) were imaged,
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and consisted of microparticles with predominantly raisin-like morphology. The
morphology of spray-dried particles is dependent on a number of process parameters
such as inlet temperature and feed concentration.55 A recent study showed that
increasing the spray drying inlet temperature from 70°C to 140°C resulted in particles
transitioning

from

spherical,

smooth

morphology to

displaying

raisin-like

morphology.56 Therefore, it is not unexpected that formulations spray-dried at an inlet
temperature of 100°C and with relatively low feed concentration (20 mg/mL) would
exhibit raisin-like morphology. A high inlet temperature and low feed concentration
causes fast vaporization of the solvent from solution and subsequent, internal bubble
nucleation, particle inflation and particle surface deformation during drying, thereby
preventing droplets from forming spherical particles.

Figure 3.11. Scanning electron microscopy images showing the morphology of raw
lopinavir (LPV), raw ritonavir (RTV), spray-dried (SD) LPV, SD RTV, and the four
final ternary complexes. β-CD = 2-hydroxypropyl-β-cyclodextrin, γ-CD = 2hydroxypropyl-γ-cyclodextrin, and SOL = Soluplus®.
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3.10 Karl Fischer Titration
Karl Fischer titration was used to determine the water content of the final ternary
formulations. As seen in Table 6, water content ranged from 1.06 to 1.24 wt%. The
moisture content of formulations is an important characteristic relating to product
stability, where low moisture content can reduce particle agglomeration as well as
prevent crystal growth formation from amorphous drug in a formulation.57 These
values indicate that dry microparticles were in fact produced, and that the spray-drying
process is capable of removing most of the moisture from the samples.

Table 6. Water content values corresponding to the final formulations determined via
Karl Fischer Titration. LPV = lopinavir, RTV = ritonavir, β-CD = 2-hydroxypropyl-βcyclodextrin, γ-CD = 2-hydroxypropyl-γ-cyclodextrin, and SOL = Soluplus®.
Formulation

Water Content (weight %)

β-CD/LPV/SOL

1.24  0.51

-CD/LPV/SOL

1.06  0.35

β-CD/RTV/SOL

1.19  0.38

-CD/RTV/SOL

1.21  0.23

3.11 In Vitro Dissolution Analysis
In vitro drug dissolution characteristics of the final formulations, their physical
mixtures, and the corresponding raw and spray-dried drugs were tested using a USP II
apparatus. Dissolution media was prepared under two different pH values, 1.1 and 6.8,
to simulate acidic conditions present in the stomach and more neutral conditions in the
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small intestine, respectively. Paddle speed was set to 75 rpm and temperature was
maintained at 37°C. In addition, non-sink conditions were used in this experiment
because in order to satisfy sink conditions, an excessive quantity of surfactant (0.06 M
polyoxyethylene 10 lauryl ether) would have been required, which does not replicate
the actual in vivo environment, and therefore may not accurately reflect the “true”
dissolution profile of the samples tested.
Figure 3.12A shows the release profiles of LPV controls and formulations
containing LPV in 0.1 N HCl. Pure LPV exhibited a cumulative release of
approximately 4% over the course of 120 minutes. The dissolution profile of spraydried LPV was analyzed to investigate the effect of crystallinity on dissolution rate.
Unexpectedly, the cumulative release of the spray-dried LPV was around 1.3% over
120 minutes, which is significantly lower than that of the pure LPV. This result
indicates that transitioning LPV from crystalline to amorphous does not necessarily
result in improved dissolution rate and extent. This was consistent with a recently
reported study,58 in which different metastable forms of LPV were studied.
Considering that LPV has four crystalline forms, it may be possible that amorphous
LPV recrystallizes to form a less soluble crystalline form of LPV under super
saturated conditions (non-sink conditions). Further studies need to be conducted to
elucidate this phenomenon. Ternary formulations (i.e. β-CD/LPV/SOL and γCD/LPV/SOL) exhibited enhanced dissolution rates over the pure drug and spraydried drug (Figure 3.12A). This is most likely due to the effects of CD complexation
aided by the addition of water-soluble polymer Soluplus® rather than LPV being
amorphous. It is worthy to note that large pieces of solid aggregates were observed
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during the dissolution testing of the ternary formulations, indicating that a significant
amount of drug may not have access to the dissolution medium and hence hampered
dissolution. In addition, the physical mixtures of CD, LPV, and SOL resulted in an
enhanced dissolution profile with a decrease in dissolution at 90 minutes followed by a
sharp increase in dissolution. This indicates that polymorphic transition may have
occurred during the dissolution testing process. It may be possible that LPV
recrystallized to form a less soluble form at 90 minutes. However, a thorough solid
state characterization study of LPV under supersaturated conditions needs to be
conducted.
A similar trend was observed when testing the physical mixture and formulations
in neutral condition (pH 6.8), as shown in Figure 3.12B. The cumulative release of
LPV from both physical mixture samples peaked around 25% after 8 hours, whereas
both formulations containing LPV exhibited a release around 9% within 8 hours.
Again, this indicates that the conversion of LPV from crystalline to amorphous form
may actually be detrimental to the dissolution rate of LPV under current testing
conditions.
The dissolution profiles of RTV controls, and formulations containing RTV in 0.1
N HCl are shown in Figure 3.12C. The cumulative release of pure RTV (in a
crystalline form) was around 32% after 2 hours. RTV has a much higher solubility in
0.1 N HCl than LPV due to protonation of the thiazole groups present in RTV.59 The
dissolution rate increased in spray-dried RTV, as a cumulative release of 58% was
observed after 2 hours. This result makes sense intuitively, as a metastable
(amorphous) form of a drug usually results in an enhanced dissolution rate compared
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to its crystalline form. Both physical mixtures containing RTV exhibited the lowest
dissolution rate out of all samples tested. In addition, both spray-dried formulations
exhibited enhanced dissolution profiles than the pure drug and physical mixtures,
although β-CD/RTV/SOL showed the fastest release profile. Based on the NMR
studies, β-CD + RTV has a lower association constant than γ-CD + RTV, and that
would allow RTV to evacuate the CD cavity quicker, leading to an enhanced release
profile. After 15 minutes, 80% of RTV was released from β-CD/RTV/SOL and 100%
drug was released after 45 minutes. A similar trend was observed when samples were
analyzed in neutral condition (pH 6.8), as shown in Figure 3.12D. Both physical
mixtures resulted in a cumulative release of less than 1%. β-CD/RTV/SOL exhibited a
cumulative release of approximately 16%, whereas γ-CD/RTV/SOL exhibited a
cumulative release of around 10%. Similarly, the formulation containing β-CD
showed a quicker dissolution, indicating that drug may be able to come out of the CD
cavity in less time than that out of the γ-CD.
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Figure 3.12. In vitro dissolution profiles of lopinavir (LPV)-contained samples in (A)
0.1 N HCl and (B) phosphate buffered saline (PBS), and ritonavir (RTV)-contained
samples in (C) 0.1 N HCl and (D) PBS. β-CD = 2-hydroxypropyl-β-cyclodextrin, γCD = 2-hydroxypropyl-γ-cyclodextrin, and SOL = Soluplus®.

Overall, these results indicate that LPV and RTV exhibit fundamentally different
physiochemical characteristics and hence different outcomes of dissolution
enhancement by forming complexes with CD. β-CD/RTV/SOL complexes showed
the most profound dissolution enhancement.
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CHAPTER 4

CONCLUSIONS AND FUTURE WORK

The interactions between two types of cyclodextrin (i.e. HP-β-CD and HP-γ-CD)
and two different anti-HIV model drugs (i.e. LPV and RTV) were thoroughly
investigated. Phase solubility studies confirmed that as CD concentration increases,
there is a corresponding increase (linear relationship) in drug solubility for both LPV
and RTV. It appears that HP-β-CD has a more significant impact on enhancing
solubility. This can be due to the smaller size of the CD cavity itself, increasing the
likelihood of interactions forming between drug and CD. In addition, it is possible
that the drugs are forming non-inclusion complexes, and LPV and RTV are interacting
with the functional groups (e.g. hydroxypropyl) on the outside of the CD and not just
with the hydrophobic interior. ITC studies were performed mainly to investigate the
binding stoichiometry between drug and CD. This information is extremely important
when deciding on the ratio of drug:CD to use in the actual formulations. It was found
that for both types of CD and both drugs, a 1:1 interaction was favored based on their
thermodynamic behavior. The negative Gibb’s free energy values indicate that the
complexation is a spontaneously exothermic process. NMR titration and molecular
modeling studies were then performed to further confirm these finding, and to closely
examine the particular the interactions that occur between the drugs and the CD. It was
shown that multiple types of intermolecular forces such as hydrogen bonding and
hydrophobic interactions play a role in the formation and drug:CD complexes.
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To further enhance the dissolution characteristics of the two model compounds, a
variety of polymers were studied. It was found that 1% Soluplus® (SOL) provided the
greatest increase in solubility for both drugs, and therefore this polymer was chosen
for further studies. Ternary complexes were prepared using drug, CD, and Soluplus®,
and then spray-dried to yield dry powder microparticles. Various solid-state
characterization techniques were used to analyze the dry complexes. SEM imaging
revealed that microparticles exhibited mainly raisin-like morphology, with sizes
ranging from 2-4 microns. DSC results showed that LPV and RTV had melting
temperatures of 113°C and 130°C. Data also suggests that spray-dried formulations
may contain amorphous drug, as indicated by the disappearance of melting
temperature peaks. XRD results confirmed this finding, as both pure LPV and pure
RTV exhibited shark, distinct peaks that disappeared in all complex formulations.
PLM images were obtained to provide visual evidence of this phenomenon. Both
drugs showed a significant degree of birefringence, indicative of crystalline structures.
On the contrary, spray-dried drug as well as binary and ternary formulations exhibited
a lack of birefringence, indicating that both drugs converted from crystalline to
amorphous during the microparticle formulation process. In this study, we were able
to successfully create spray-dried microparticles and characterize them based on their
solid-state properties.
In vitro dissolution study showed that LPV and RTV had vastly different release
profiles in both conditions, and that the effect of crystallinity had a different impact on
each drug. For LPV, the physical mixture of LPV, CD, and SOL provided the greatest
release profile. It was also found that spray-dried LPV did not offer any dissolution
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enhancement, and in fact resulted in a lower release profile. On the other hand, the
release rate of RTV was drastically enhanced in both formulations containing RTV,
CD, and SOL, when compared to the controls. In addition, it was found that spraydried RTV exhibited a better dissolution profile than crystalline drug, therefore
indicating that spray-drying has a positive effect on overall RTV dissolution kinetics.
Ternary RTV:CD complexes were able to successfully enhance dissolution rate and
extent when compared to the controls.
Based on these findings, a different formulation technique will be required to
enhance solubility and dissolution profile of LPV. It appears that converting LPV from
crystalline to amorphous form via spray drying adversely affected dissolution
characteristics of LPV, and therefore other methods such as kneading and
lyophilization that do not involve high temperature will be studied. The taste
assessment study of the optimized formulations will be performed to assess tastemasking capability of CD. In addition, stability studies will be conducted to analyze
the effects of CD and SOL on the stability of both drugs. Following these studies, oral
bioavailability study of the optimized formulations will be performed using a rat
model.
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APPENDIX

Figure A.1. Schematic showing the phase solubility profiles and classification of
complexes according to Higuchi and Connors.36

Figure A.2. NMR titration spectra for lopinavir (LPV) and 2-hydroxypropyl-βcyclodextrin (β-CD).

57

Figure A.3. NMR titration spectra for lopinavir (LPV) and 2-hydroxypropyl-γcyclodextrin (γ-CD).

Figure A.4. NMR titration spectra for ritonavir (RTV) and 2-hydroxypropyl-γcyclodextrin (β-CD).
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Figure A.5. NMR titration spectra for ritonavir (RTV) and 2-hydroxypropyl-γcyclodextrin (γ-CD).

Figure A.6. Stacked NMR spectra of lopinavir (LPV), 2-hydroxypropyl-βcyclodextrin (β-CD), and a 1:1 molar solution of β-CD:LPV.
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Figure A.7. Stacked NMR spectra of lopinavir (LPV), 2-hydroxypropyl-γcyclodextrin (γ-CD), and a 1:1 molar solution of γ-CD:LPV.

Figure A.8. Stacked NMR spectra of ritonavir (RTV), 2-hydroxypropyl-βcyclodextrin (β-CD), and a 1:1 molar solution of β-CD:RTV.
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Figure A.9. Stacked NMR spectra of ritonavir (RTV), 2-hydroxypropyl-γcyclodextrin (γ-CD), and a 1:1 molar solution of γ-CD:RTV.

Figure A.10. Solubility analysis of (Top) pure lopinavir (LPV) and ternary complexes
including β-CD/LPV/SOL and γ-CD/LPV/SOL and (Bottom) pure RTV and ternary
complexes including β-CD/RTV/SOL and γ-CD/RTV/SOL (* p<0.05, *** p<0.001).
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